Cardinal Health to Announce Third-Quarter Results for Fiscal Year 2026 on April 30 Accessibility StatementSkip NavigationDUBLIN, Ohio, March 24, 2026 /PRNewswire/ -- Cardinal Health (NYSE: CAH) plans to release third-quarter financial results for its fiscal year 2026 on April 30 as previously indicated, prior to the opening of trading on the New York Stock Exchange. The company will webcast a discussion of these results beginning at 8:30 a.m. Eastern.To access the webcast and corresponding slide presentatio ...

Cardinal Health Appoints Patricia A. Hemingway Hall as Board Chair Accessibility StatementSkip NavigationDUBLIN, Ohio, March 23, 2026 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today announced that its Board of Directors has appointed Patricia A. Hemingway Hall to succeed Gregory B. Kenny as Chair of the Board following Mr. Kenny's retirement, effective immediately.Mr. Kenny has served on the Board since 2007 and as Chairman since 2018. During his tenure on the Board, Mr. Kenny supported the Company throug ...

Core Insights - The presentation focuses on the recent earnings results of Henry Schein and provides guidance for 2026, highlighting significant transitions within the company [1][3]. Group 1: Earnings Highlights - Henry Schein reported positive results for the fourth quarter, indicating overall satisfaction with the performance [4]. - The dental distribution segment showed improving growth both in the U.S. and internationally, suggesting an increase in market share [4]. - There was a notable recovery in distribution growth after experiencing negative growth in the second quarter, attributed to successful promotional programs [4].

Segment Performance - Global Distribution and Value-Added Services sales rose 7.0% to $2.89 billion in the fourth quarter, up 5.2% on a constant-currency basis from the year-ago period [1] - Global Specialty Products sales increased 14.6% to $422 million, or 11.1% in constant currency, driven by strong dental implant demand and solid growth in endodontics [1] - Global Technology sales climbed 8.4% to $173 million, up 7.6% in constant currency from the fourth quarter of 2024, reflecting accelerated adoption of cloud-based software and revenue from newly launched solutions [2] Management Commentary - The growth achieved, especially over the second half of 2025, demonstrates the effective execution of the 2025-2027 BOLD+1 strategic plan, positioning the company well for the future [3] Guidance - The company expects fiscal 2026 adjusted earnings of $5.23-$5.37 per share compared to the consensus of $5.30 [4] - Projected sales for 2026 are $13.58 billion-$13.84 billion, reflecting a year-over-year growth of 3% to 5% from fiscal 2025 sales of $13.18 billion [4] - 2026 adjusted EBITDA is expected to grow in mid-single digits compared with 2025 [5] Analyst View - Strength in the specialty segment is an encouraging sign for the company's ability to drive higher margin mix and for dental end-markets, given the specialty portfolio's high exposure to out-of-pocket procedures like dental implants [6] - Initial 2026 guidance is in line with or slightly ahead of the Street, indicating stability and improving results [6] - The first read on the quarter is viewed as a positive step with improving end-markets and execution on key segments like specialty products [6] HSIC Price Action - Henry Schein shares were up 5.01% at $83.57, trading at a new 52-week high [7]

Core Insights - Henry Schein, Inc. (HSIC) reported fourth-quarter 2025 adjusted earnings per share (EPS) of $1.34, reflecting a 12.6% increase year-over-year and surpassing the Zacks Consensus Estimate by 3.1% [1] - The full-year 2025 adjusted EPS was $4.97, up 4.8% from the previous year, also exceeding the Zacks Consensus Estimate by 1.2% [2] Revenue Performance - Fourth-quarter net sales reached $3.44 billion, a 7.8% increase year-over-year, beating the Zacks Consensus Estimate by 3.1% [3] - Full-year 2025 net sales totaled $13.18 billion, up 4% year-over-year, also surpassing the Zacks Consensus Estimate by 0.8% [3] Segment Analysis - Global Distribution and Value-Added Services segment sales rose 7% year-over-year to $2.89 billion, exceeding the forecast of $2.81 billion [4] - Global Dental Distribution merchandise sales increased 3.7% in constant currencies, while equipment sales grew by 9.1% at constant currencies, driven by strong growth in key markets [5] - Global Medical Distribution sales jumped 4.8% at constant currencies, despite a decline in the respiratory product category [5] - Global Specialty Products sales totaled $422 million, up 14.6% on a reported basis, reflecting strong growth in dental implants and endodontics [6] - Global Technology segment sales reached $173 million, an 8.4% increase on a reported basis, driven by cloud-based software adoption [7] Margin Performance - Gross profit for the quarter was $1.06 billion, a 7% increase year-over-year, but gross margin contracted by 19 basis points to 30.9% due to an 8% rise in the cost of sales [9] - SG&A expenses increased by 9.5% to $808 million, with adjusted operating profit remaining flat year-over-year at $255 million, leading to a contraction of the adjusted operating margin by 57 basis points to 7.4% [9] Liquidity and Share Repurchase - At the end of Q4 2025, the company had cash and cash equivalents of $156 million, up from $122 million a year earlier [10] - The cumulative net cash provided by operating activities was $712 million, down from $848 million in the previous year [10] - The company repurchased nearly 2.8 million shares at an average price of $71.10 per share, totaling approximately $200 million, with $780 million authorized for future repurchases [11] Future Guidance - For 2026, the company expects total sales growth between 3% and 5%, with the Zacks Consensus Estimate for sales at $13.53 billion, indicating a 3.5% year-over-year growth [12] - Non-GAAP diluted EPS for 2026 is projected to be in the range of $5.23 to $5.37, with the Zacks Consensus Estimate at $5.27 [12] Overall Assessment - The company demonstrated strong earnings and revenue growth, exceeding estimates, although margin contraction is a concern [13] - Solid sales growth was observed across all business segments, particularly in global equipment, specialty products, and technology [13]

Financial Data and Key Metrics Changes - Global sales for Q4 2025 reached $3.4 billion, reflecting a sales growth of 7.7% compared to Q4 2024, with constant currency sales growth of 5.8% and a 1.9% increase from foreign currency exchange [29] - GAAP operating margin for Q4 2025 was 4.76%, a decrease of 10 basis points from the prior year, while non-GAAP operating margin was 7.42%, relatively flat compared to the prior year [30] - Q4 2025 GAAP net income was $101 million or $0.85 per diluted share, compared to $94 million or $0.74 per diluted share in the prior year [30] - Non-GAAP net income for Q4 2025 was $160 million or $1.34 per diluted share, compared to $149 million or $1.19 per diluted share in the prior year [31] Business Line Data and Key Metrics Changes - Global distribution and value-added services group sales grew by 7.0%, with U.S. dental merchandise sales increasing by 3.6% and U.S. dental equipment sales growing by 10.6% [32] - Global specialty products group sales grew by 14.6%, driven by strong performance in implants and biomaterials [33] - Global technology group sales grew by 8.4%, with significant contributions from practice management software [33] Market Data and Key Metrics Changes - U.S. dental merchandise sales growth reflected continued market share gains, with January 2026 sales showing good momentum [18] - International dental merchandise sales grew by 9.2% in constant currencies, with strong growth across Southern and Eastern Europe, Germany, Brazil, and Canada [32] - U.S. medical distribution sales grew by 4.9%, reflecting strong growth in home solutions, while international dental equipment sales grew by 13.9% [32][33] Company Strategy and Development Direction - The company is executing its 2025-2027 BOLD+1 strategic plan, with non-GAAP operating income from high-growth, high-margin businesses approaching 50% of total operating income [12][13] - The rollout of the global e-commerce platform, henryschein.com, is underway, with expectations to complete the rollout to U.S. Dental and Canadian customers in Q1 2026 [14] - The company is focusing on innovative solutions to enhance patient care and operational efficiency, including partnerships with Amazon Web Services for AI integration [14][27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the stability of the U.S. dental market, with positive trends in patient traffic and dentist investments in technology [51][54] - The company anticipates earnings growth to be more heavily weighted towards the second half of 2026 due to ongoing value creation initiatives [58] - Management noted that the international dental equipment market is performing well, with broad-based growth across many countries [23][32] Other Important Information - The company repurchased approximately 2.8 million shares of common stock at an average price of $71.10 per share, totaling $200 million [35] - Operating cash flow for Q4 2025 was $381 million, compared to $204 million in Q4 2024, driven by working capital management [36] Q&A Session Summary Question: Guidance on operating income improvement plan - Management indicated that the benefits from value creation initiatives will be more heavily weighted to the back half of the year, with some lumpiness expected in the first half [43][44] Question: Growth in specialty value implants - Management noted strong growth in specialty value implants and indicated stable pricing within the market, with no unusual price increases [46][48] Question: Durability of dental market performance - Management confirmed that the U.S. dental market is stable and leaning positively, with good feelings among dentists regarding investments in technology [50][54] Question: Sustainability of implant performance - Management expressed optimism about the implant market, particularly in Europe, while noting that U.S. growth is currently less than 5% [72][73]

Financial Data and Key Metrics Changes - Global sales for Q4 2025 reached $3.4 billion, reflecting a sales growth of 7.7% compared to Q4 2024, with constant currency sales growth of 5.8% and a 1.9% increase from foreign currency exchange [29][30] - GAAP operating margin for Q4 2025 was 4.76%, a decrease of 10 basis points from the prior year, while non-GAAP operating margin was 7.42%, relatively flat compared to the previous year [30] - Q4 2025 GAAP net income was $101 million or $0.85 per diluted share, compared to $94 million or $0.74 per diluted share in the prior year [30][31] Business Line Data and Key Metrics Changes - Global distribution and value-added services group sales grew by 7.0%, with U.S. dental merchandise sales increasing by 3.6% and U.S. dental equipment sales growing by 10.6% [32] - Global specialty products group sales grew by 14.6%, driven by strong performance in implants and biomaterials, with double-digit growth in value implants [33][24] - Global technology group sales increased by 8.4%, with significant growth in practice management software, particularly Dentrix Ascend [33][26] Market Data and Key Metrics Changes - International dental merchandise sales grew by 9.2%, with strong performance across Southern and Eastern Europe, Germany, Brazil, and Canada [32] - U.S. medical distribution sales grew by 4.9%, reflecting strong demand in home solutions, although respiratory product demand decreased [21][22] - International dental equipment sales grew by 13.9%, with broad-based growth across many countries and equipment categories [32][23] Company Strategy and Development Direction - The company is executing its 2025-2027 BOLD+1 strategic plan, with non-GAAP operating income from high-growth, high-margin businesses approaching 50% of total operating income [12] - The rollout of the global e-commerce platform, henryschein.com, is underway, with expectations to complete the rollout to U.S. Dental and Canadian customers in Q1 2026 [13] - The company is focusing on innovative solutions to enhance patient care and operational efficiency, including partnerships with Amazon Web Services for AI integration [14][27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the stability and positive trends in the U.S. dental market, with indications of increased patient traffic and investment in technology by dentists [52][54] - The company anticipates earnings growth to be more heavily weighted towards the second half of 2026 due to ongoing value creation initiatives [58] - Management noted that the market is stable, with positive sentiment among dentists regarding investments in new technologies [52][54] Other Important Information - The company repurchased approximately 2.8 million shares of common stock at an average price of $71.10 per share, totaling $200 million [36] - The effective tax rate for Q4 2025 on a non-GAAP basis was 22.7%, compared to 22% for Q4 2024 [30] - The company expects 2026 sales growth to be in the range of 3%-5% over 2025, with non-GAAP diluted EPS projected to be between $5.23 and $5.37 [38] Q&A Session Summary Question: Guidance on operating income improvement plan - Management indicated that the benefits from value creation initiatives will be more heavily weighted to the back half of the year, with some lumpiness expected in the first half [44][58] Question: Growth in specialty value implants - Management noted strong growth in specialty value implants and indicated stable pricing within the market, with no unusual price increases [47][49] Question: Durability of dental market performance - Management confirmed that the dental market is stable and leaning positively, with good feelings among dentists about investing in technology [52][54] Question: Sustainability of implant performance - Management expressed optimism about the implant market, particularly in Europe, while noting that U.S. growth is more stable but not as robust [70][72]

Financial Data and Key Metrics Changes - Global sales for Q4 2025 reached $3.4 billion, reflecting a sales growth of 7.7% compared to Q4 2024, with constant currency sales growth of 5.8% and a 1.9% increase from foreign currency exchange [28][29] - GAAP operating margin for Q4 2025 was 4.76%, a decrease of 10 basis points from the prior year, while non-GAAP operating margin was 7.42%, relatively flat compared to the prior year [29] - Q4 2025 GAAP net income was $101 million or $0.85 per diluted share, compared to $94 million or $0.74 per diluted share in the prior year [30] - Non-GAAP net income for Q4 2025 was $160 million or $1.34 per diluted share, compared to $149 million or $1.19 per diluted share in the prior year [31] Business Line Data and Key Metrics Changes - Global distribution and value-added services group sales grew by 7.0%, with U.S. dental merchandise sales increasing by 3.6% and U.S. dental equipment sales growing by 10.6% [32] - International dental merchandise sales grew by 9.2%, driven by growth across Southern and Eastern Europe, Germany, Brazil, and Canada [32] - Global specialty products group sales increased by 14.6%, with strong performance in implants and biomaterials, particularly in Germany, Brazil, and France [22][33] Market Data and Key Metrics Changes - U.S. medical distribution sales grew by 4.9%, reflecting strong growth in home solutions, while international dental equipment sales grew by 13.9% [32][33] - The U.S. dental market showed signs of stability and positive trends, with patient traffic remaining stable and a slight positive lean observed [15][51] - International equipment sales growth was broad-based, benefiting from currency exchange rates [21] Company Strategy and Development Direction - The company is executing its 2025-2027 BOLD+1 strategic plan, with non-GAAP operating income from high-growth, high-margin businesses approaching 50% of total operating income [11] - Significant progress has been made in rolling out the global e-commerce platform, henryschein.com, and partnerships with Amazon Web Services for AI integration [12][26] - The company aims to achieve over $200 million in operating income improvement through value creation initiatives, including cost savings and capturing incremental gross margin opportunities [34] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the stability of the U.S. dental market and the positive sentiment among dentists regarding investments in new technologies [51] - The company anticipates earnings growth to be more heavily weighted towards the second half of 2026 due to the timing of value creation initiatives [58] - Management noted that the overall market for dental implants is stable, with positive momentum in international markets, particularly in Germany [72] Other Important Information - The company repurchased approximately 2.8 million shares of common stock at an average price of $71.10 per share, totaling $200 million [35] - Operating cash flow for Q4 2025 was $381 million, compared to $204 million in Q4 2024, driven by effective working capital management [36] Q&A Session Summary Question: Guidance on operating income improvement plan - Management indicated that the benefits from the $125 million run rate will be more heavily weighted to the back half of the year, with some lumpiness expected in the quarters [41][42] Question: Growth in specialty value implants - Management noted strong growth in specialty value implants and indicated stable pricing within the market, with no unusual price increases observed [45][48] Question: Durability of market performance - Management confirmed that the U.S. dental market is stable and leaning positively, with good feelings among dentists about investing in new technologies [50][51] Question: Sustainability of implant performance - Management expressed optimism about the sustainability of implant performance, particularly in international markets, while noting that U.S. growth is more stable but less robust [67][72]

Q4 2025 Earnings Conference Call Financial Results & Outlook February 24, 2026 1 Cautionary Note Regarding Forward-Looking Statements and Use of Non-GAAP Financial Information In accordance with the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995, we provide the following cautionary remarks regarding important factors that, among others, could cause future results to differ materially from the forward-looking statements, expectations and assumptions expressed or implied here ...

Core Insights - Cardinal Health, Inc. reported strong second-quarter fiscal 2026 results, with adjusted earnings per share (EPS) of $2.63, exceeding estimates by 10% and showing a year-over-year increase of 36.3% [1][8] - The company raised its fiscal 2026 EPS guidance to between $10.15 and $10.35, reflecting confidence in continued strong performance across segments [10][19] Revenue Performance - Total sales increased by 18.6% year-over-year to $65.6 billion, surpassing consensus estimates by 0.9% [2] - Pharmaceutical revenues rose by 19.3% to $60.67 billion, driven by growth in branded and specialty pharmaceutical sales [3] - The Global Medical Products and Distribution segment reported revenues of $3.26 billion, up 3.3% year-over-year [4] - The Other segment, which includes at-Home Solutions and other services, saw sales of $1.72 billion, a significant increase of 34.4% year-over-year [5] Profitability Analysis - Overall gross profit increased by 23.5% year-over-year to $2.4 billion, with a gross margin of 3.7%, up almost 15 basis points [7] - The Pharmaceutical segment's profit reached $687 million, up 29.4% from the previous year, driven by brand and specialty products [4] - The Other segment's profit amounted to $179 million, reflecting a 51.7% increase year-over-year [6] Segment Outlook - The company expects Pharmaceutical segment revenues to grow by 11-13% year-over-year, with segment profit anticipated to increase by 20-22% [11] - Medical segment revenues are projected to grow by 2-4%, with profits expected to be around $150 million [11] - The Other segment is expected to see revenue growth of 26-28% and profit growth of 33-35% [12] Strategic Initiatives - The recent acquisition of Solaris is expected to enhance sales growth in the latter half of 2026, particularly in the Urology MSO space [15] - The launch of the ContinuCare Pathway program aims to improve diabetes supply management and patient access, with significant enrollment from Publix Super Markets [18] - Strong momentum in MSO platforms and anticipated growth in BioPharma Solutions sales are expected to support Specialty revenues to exceed $50 billion in fiscal 2026 [19]